<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6418">
  <stage>Registered</stage>
  <submitdate>27/02/2017</submitdate>
  <approvaldate>27/02/2017</approvaldate>
  <nctid>NCT03073278</nctid>
  <trial_identification>
    <studytitle>Focal Radiotherapy for Previously Treated Prostate Cancer Patients</studytitle>
    <scientifictitle>Phase I Feasibility Trial of Stereotactic Re-irradiation of Prostate Cancer Recurrence Within the Definitively Irradiated Prostate</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Focal SBRT prostate</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Locally Recurrent Prostate Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Prostate</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: other - Stereotactic Body Radiotherapy

Other: Group 1 - This group of 12 patients will be given 36Gy of Stereotactic Body Radiotherapy (SBRT) divided into six separate doses. This will be delivered two to three time per week.

Other: Group 2 - This group (12 patients) will be given 38Gy of Stereotactic Body Radiotherapy (SBRT) divided into six separate doses. This will be delivered two to three time per week.

Other: group 3 - This group (12 patients) will be given 40Gy of Stereotactic Body Radiotherapy (SBRT) divided into six separate doses. This will be delivered two to three time per week.


Treatment: other: Stereotactic Body Radiotherapy
Each group will have different dose of stereotactic body radiotherapy (SBRT). Depending on which group patients are in.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>feasibility of SBRT dose escalation. This will be assessed by the number of participants with grade 3 acute toxicity according to CTCAE version 4.3 - acute toxicity will be assessed weekly during treatment period to check whether dose escalation can be achieved</outcome>
      <timepoint>at weekly review through completion of each radiothrapy dose level, approximately one year</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>safety of SBRT dose escalation. This will be assessed by the number of participants with grade 3 acute toxicity according to CTCAE version 4.3 - outcome will be assessed by reviewing toxicity weekly during the treatment period and at the end of each dose escalation</outcome>
      <timepoint>at weekly review through completion of each radiothrapy dose level, approximately one year</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Toxicity. This will be assessed by the number of participants with grade 3 acute toxicity according to CTCAE version 4.3 and RTOG toxicity score. - outcome will be assessed by reviewing toxicity weekly and at the end of each dose escalation</outcome>
      <timepoint>at weekly review through completion of each radiothrapy dose level, approximately one year</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Tolerability of conservation dose escalation in this cohort of patients - outcome will be assessed by reviewing toxicity weekly or secondly weekly and at the end of each dose escalation</outcome>
      <timepoint>After each group of patients have completed radiotherapy and at 12 and 24 months follow-up. Patients will have routine follow-up 6 monthly for 1 year and then yearly for 10 years post treatment. But study outcomes will only be collected for 2 years.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Men &gt; 4yrs from external beam radiotherapy (EBRT) meeting the Phoenix definition of
             biochemical failure or men &gt; 5yrs from EBRT if neo-adjuvant and/or adjuvant androgen
             deprivation therapy (ADT) also used

          -  Recurrence localised to less than 1 lobe of prostate on both PMSA and multi-parametric
             MRI (less than equal to cT2a)

          -  Recurrence must be biopsy proven, with positive biopsies limited to the PET and MRI
             suspicious region.

          -  Life expectancy at least 10yrs from time of SBRT

          -  PSA &lt; 10</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Recurrence in immediate proximity to rectum (unless able to have hydrogel)

          -  Grade 3 or more toxicity from previous EBRT

          -  Contra-indicated for fiducial insertion

          -  GS 8,9 or 10 disease previously (relative - consider if decent disease free interval)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Other</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>24/04/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>36</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>31/03/2024</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Royal North Shore Hospital - St Leonards</hospital>
    <postcode>2065 - St Leonards</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Royal North Shore Hospital</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To examine the feasibility, safety and toxicity of focal stereotactic radiation treatment
      (SBRT) for locally recurrent prostate cancer.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03073278</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>George Hruby</name>
      <address>Northern Sydney Local Health District</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Carolyn Kwong</name>
      <address />
      <phone>+61 2 9463 1339</phone>
      <fax />
      <email>carolyn.kwong@health.nsw.gov.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>